1357.HK
Meitu announced on Monday it recorded a net profit of 228 million yuan in the first half of 2023, reversing a net loss of 266 million yuan in the same period last year.

The latest: Chinese beauty app Meitu Inc. (1357.HK) announced on Monday it recorded a net profit of 228 million yuan ($31.3 million) in the first half of 2023, reversing a net loss of 266 million yuan in the same period last year. Its non-IFRS net profit surged 320% to 151 million yuan.

Looking up: Revenue from the company’s photo, video and design products jumped 62.2% to 602 million yuan, benefiting from higher VIP subscription rates, making it Meitu’s largest revenue source and fueling a 29.8% overall revenue increase to 1.26 billion yuan.

Take Note: The company’s R&D expenses rose by 10.8% to 294 million yuan, due to increased investment in its artificial intelligence generated content (AIGC) technologies.

Digging Deeper: Founded in 2008 and listed in Hong Kong in 2016, Meitu began as operator of a consumer-oriented beauty app for editing photos. It later started providing B2B services to businesses like cosmetic shops and photo studios. Since shifting its focus to business-, rather than consumer-oriented, customers, the company’s revenues have grown significantly, and it recorded its first-ever net profit of 94.14 million yuan last year. Entering 2023, the strong growth in VIP subscriptions and a one-time gain of 186 million yuan related to cryptocurrency investments helped to significantly improve its profits.

Market Reaction: Meitu shares jumped on Tuesday to close up 19.3% at HK$2.91 by the midday break. The stock now trades at the upper end of its 52-week range.

Translation by A. Au

Have a great investment idea but don’t know how to spread the word? We can help! Contact us for more details.

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…